Role of BRCA1 mutation screening in the management of familial ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 175, Issue 3 PART I, 1996, Pages 738-746

  Berchuck, Andrew ^a   Cirisano, Frank ^a   Lancaster, Johnathan M ^c   Schildkraut, Joellen M ^b   Wiseman, Roger W ^c   Futreal, Andrew ^a,b   Marks, Jeffrey R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

BRCA1 gene; Breast cancer; Familial ovarian cancer

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; CHROMOSOME 17Q; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT;

CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, BRCA1; GENETIC SCREENING; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PEDIGREE;

EID: 0029803838     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1053/ob.1996.v175.a74288     Document Type: Article

References (61)

1. Lynch HT, Albano W, Black L, Lynch JF, Recabaren J, Pierson R. Familial excess of cancer of the ovary and other anatomic sites. JAMA 1981;245:261-4.
2. Fraumeni JF Jr, Grundy GW, Creagen ET, Everson RB. Six families prone to ovarian cancer. Cancer 1975;36:364-9.
3. Lynch HT, Harris RE, Guirgis HA, Maloney K, Carmody LL, Lynch JF. Familial association of breast/ovarian carcinoma. Cancer 1978;41:1543-9.
4. Piver MS, Barlow JJ, Sawyer DM. Familial ovarian cancer: increasing in frequency? Obstet Gynecol 1982;60:397-400.
5. Piver MS, Mettlin CJ, Tsukada Y, Nasca P, Greenwald P, McPhee ME. Familial ovarian cancer registry. Obstet Gynecol 1984;64:195-9.
6. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993;71:582-8.
7. Amos CI, Shaw GL, Tucker MA, Hartge P. Age at onset for familial epithelial ovarian cancer. JAMA 1992;268:1896-9.
8. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992;80:700-7.
9. Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A. Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol 1982;59:589-96.
10. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988;128:456-66.
11. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian relationship. Am J Hum Genet 1989;4:521-9.
12. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
13. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28:115-20.
14. Hall J, Lee M, Newman B, Morrow J, Huey B, King MC. Linkage of early onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
15. Narod SA, Feunteun J, Lynch HT, et al. Familial breastovarian cancer locus on chromosome 17ql2-q23. Lancet 1991;338:82-3.
16. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
17. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 1995;273:535-41.
18. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCAl-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
19. Jensen RA, Thompson ME, Jetton TL, et al. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 1996;55:303-8.
20. Gudas JM, Nguyen H, Li T, Cowan KH. Hormone dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561-5.
21. Boyd M, Harris F, McFarlane R, Davidson HR, Black DM. A human BRCA1 gene knockout. Nature 1995;375:541-2.
22. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
23. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A 1993;90:10914-21.
24. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
25. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992;2:128-131.
26. Holt JT, Thompson ME, Szabo CI, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298-302.
27. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
28. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Invest 1994;1:181-90.
29. Jacobs IJ, Smith S, Wiseman R, et al. A deletion unit on chromosome 17q defined by loss of heterozygosity in epithelial ovarian cancer and a benign serous cystadenoma. Cancer Res 1993;53:1218-21.
30. Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, et al. Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer. Am J Obstet Gynecol 1995;172:908-13.
31. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
32. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
33. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995;9:439-43.
34. Hosking L, Trowsdale J, Nicolai H, et al. A somatic BRCA1 mutation in an ovarian tumour. Nat Genet 1995;9:343-4.
35. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-50.
36. Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995;270:789-91.
37. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993;269:1970-4.
38. Simard J, Tonin P, Durocher F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
39. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
40. Castilla LH, Couch FJ, Erdos MR, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387-91.
41. Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
42. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
43. Steichen-Gersdorf E, Gallion HH, Ford D, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994;55:870-5.
44. Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995;57: 957-8.
45. Nystrom-Lahti M, Parsons R, Sistonen P, et al. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet 1994;55:659-65.
46. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994:265:2088-90.
47. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378: 789-91.
48. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995;72:805-12.
49. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994;55:i-iv.
50. Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families: Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:254-264.
51. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer; results from 214 families: the Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
52. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for genotype-phenotype correlation. Nat Genet 1995;11:428-33.
53. Hammond CB. Menopause and hormonal replacement therapy: an overview. Obstet Gynecol 1996;87:2-15S.
54. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;2:795-7.
55. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71: 2751-5.
56. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of twelve US casecontrol studies, IV: the pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992;136:1212-20.
57. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 1995;273:577-85.
58. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogenreceptor-positive tumors. N Engl J Med 1989;320:479-84.
59. The Ad Hoc Committee on genetic testing/insurance issues, genetic testing and insurance. Am J Hum Genet 1995;56: 327-31.
60. Lynch HT, Severin MJ, Mooney MJ, Lynch J. Insurance adjudication favoring prophylactic surgery in heritable breastovarian cancer syndrome. Gynecol Oncol 1995;57:23-6.
61. Lancaster JM, Wiseman RW, Berchuck A. An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast/ovarian cancer susceptibility gene. Obstet Gynecol 1996;87:306-9.